<DOC>
	<DOCNO>NCT01572740</DOCNO>
	<brief_summary>This trial conduct Asia . The purpose trial investigate efficacy safety liraglutide combination insulin therapy compare insulin alone Japanese subject type 2 diabetes mellitus . Subjects remain pre-trial insulin therapy .</brief_summary>
	<brief_title>Efficacy Safety Liraglutide Combination With Insulin Therapy Compared Insulin Alone Japanese Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes mellitus ( diagnose clinically ) least 6 month Current insulin therapy ( basal insulin , premixed insulin basalbolus regimen ) addition diet exercise therapy least 12 week prior trial start . Their therapy stable fluctuation total daily insulin dose within plus/minus 20 % least 12 week prior trial start current total daily insulin dose equal great 10 ( I ) U/day Glycosylated haemoglobin ( HbA1c ) 7.5 11.0 % ( inclusive ) Body Mass Index ( BMI ) 45.0 kg/m^2 Anticipated change concomitant medication know interfere significantly glucose metabolism , , limited systemic corticosteroid , betaantagonists monoamine oxidase ( MAO ) inhibitor Recurrent severe hypoglycaemia ( 1 severe hypoglycaemic episode last 12 month ) hypoglycaemic unawareness judge investigator hospitalisation diabetic ketoacidosis previous 6 month Known proliferative retinopathy maculopathy require treatment accord investigator Treatment glucagonlike peptide1 ( GLP1 ) receptor agonist within 12 week prior screen Treatment oral antidiabetic drug ( OADs ) within 12 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>